Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Research from University of Michigan scientists reveals Vegf-Notch signaling system that is activated in the injured retina, gives Muller glia stem cell properties.
An international team led by Harvard Medical School scientists has discovered a new genetic mutation that may be a root cause of severe cases of childhood glaucoma, a devastating condition that runs in families.
A pilot study of 106 patients with “wet” AMD revealed that nearly half of patients treated with Eylea could safely stop therapy after one year, compared to only 17% of patients treated with Avastin.
A new study from Duke University finds that single neurons conveying visual information about two separate objects in sight do so by alternating signals about one or the other.
Researchers from the University of Illinois shed light on how neural stem cells called neuroblasts divide multiple times to sequentially produce neurons of specialized function.
Jordan Hamm, an assistant professor of neuroscience at Georgia State University, has received a five-year, $1.93 million award from the National Eye Institute.
Rogue clinics offer stem cell-based therapies that haven’t been tested for safety and efficacy. When communicating to the public about stem cell-based therapies, it is important to put any treatment claims in context.